Journal Article

Mutation Analysis of Pancreatic Juice and Plasma for the Detection of Pancreatic Cancer

van IJcken, Wilfred, van Marion, Ronald, Jansen, Maurice P. H. M., Azmani, Zakia, Cahen, Djuna L., Peppelenbosch, Maikel P., Fuhler, Gwenny M., Bruno, Marco J., Levink, Iris J. M.

2023

Overview

Molecular profiling may enable earlier detection of pancreatic cancer (PC) in high-risk individuals undergoing surveillance and allow for personalization of treatment. We hypothesized that the detection rate of DNA mutations is higher in pancreatic juice (PJ) than in plasma due to its closer contact with the pancreatic ductal system, from which pancreatic cancer cells originate, and higher overall cell-free DNA (cfDNA) concentrations. In this study, we included patients with pathology-proven PC or intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia (HGD) from two prospective clinical trials (KRASPanc and PACYFIC) for whom both PJ and plasma were available. We performed next-generation sequencing on PJ, plasma, and tissue samples and described the presence (and concordance) of mutations in these biomaterials. This study included 26 patients (25 PC and 1 IPMN with HGD), of which 7 were women (27%), with a median age of 71 years (IQR 12) and a median BMI of 23 kg/m2 (IQR 4). Ten patients with PC (40%) were (borderline) resectable at baseline. Tissue was available from six patients (resection n = 5, biopsy n = 1). A median volume of 2.9 mL plasma (IQR 1.0 mL) and 0.7 mL PJ (IQR 0.1 mL, p < 0.001) was used for DNA isolation. PJ had a higher median cfDNA concentration (2.6 ng/μL (IQR 4.2)) than plasma (0.29 ng/μL (IQR 0.40)). A total of 41 unique somatic mutations were detected: 24 mutations in plasma (2 KRAS, 15 TP53, 2 SMAD4, 3 CDKN2A 1 CTNNB1, and 1 PIK3CA), 19 in PJ (3 KRAS, 15 TP53, and 1 SMAD4), and 8 in tissue (2 KRAS, 2 CDKN2A, and 4 TP53). The mutation detection rate (and the concordance with tissue) did not differ between plasma and PJ. In conclusion, while the concentration of cfDNA was indeed higher in PJ than in plasma, the mutation detection rate was not different. A few cancer-associated genetic variants were detected in both biomaterials. Further research is needed to increase the detection rate and assess the performance and suitability of plasma and PJ for PC (early) detection.

• Publisher: MDPI AG,MDPI
• Subject: Biocompatible Materials / Biological products / Biomarkers / Biopsy / Cancer / Cell-Free Nucleic Acids - genetics / Chemotherapy / Child / Cloning / Communication / Diagnosis / Female / Genetic aspects / Genetic research / Humans / Male / Mutation / Oncology, Experimental / Pancreatic cancer / Pancreatic Intraductal Neoplasms / Pancreatic Juice / Pancreatic Neoplasms / Pancreatic Neoplasms - diagnosis / Pancreatic Neoplasms - genetics / Patients / Plasma / Prospective Studies / Proto-Oncogene Proteins p21(ras) - genetics / Surveillance / Tumor proteins